08:00 , Nov 3, 2014 |  BioCentury  |  Finance

Shooting F-stars

F-star Alpha Ltd. 's deal with Bristol-Myers Squibb Co. (NYSE:BMY) last week is the first validation of the parent platform company's strategy of speeding returns by packaging assets into corporations for buyer convenience and seller...
07:00 , Aug 4, 2014 |  BioCentury  |  Finance

Voucher leapfrog

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are hoping to use a newly acquired Priority Review voucher to jump ahead of Amgen Inc. (NASDAQ:AMGN) in the race to be first to market with a...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Takeda Pharmaceutical Co. Ltd sales and marketing update

Takeda launched Zacras azilsartan/amlodipine besylate in Japan to treat hypertension. The once-daily, fixed-dose combination of azilsartan and amlodipine besylate has a Japanese National Health Insurance (NHI) list price of Y140.6 ($1.38) per tablet for both...
07:00 , May 12, 2014 |  BioCentury  |  Finance

Zeroing in on immunity

Investors in Anokion S.A. 's CHF33 million ($37.6 million) series A round think the company's antigen-specific approach to inducing immune tolerance will lead to less immunogenic formulations of existing cancer and hematology drugs, as well...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Clinical News

Zacras azilsartan/amlodipine besylate regulatory update

Takeda said Japan's Ministry of Health, Labor and Welfare (MHLW) approved an NDA for Zacras, a fixed-dose combination of azilsartan and amlodipine besylate, to treat hypertension. Azilva azilsartan, a once-daily angiotensin II type 1 (AT1)...
08:00 , Dec 16, 2013 |  BioCentury  |  Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Company News

Arbor Pharmaceuticals, Takeda sales and marketing update

Takeda granted Arbor's Arbor Pharmaceuticals Ireland Ltd. subsidiary exclusive rights to commercialize hypertension drugs Edarbi azilsartan medoxomil and Edarbyclor azilsartan medoxomil/chlorthalidone in the U.S. Takeda, which has already launched the products in the U.S., will...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Clinical News

Azilva azilsartan/amlodipine besylate regulatory update

Takeda submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for a fixed-dose combination of Azilva azilsartan and amlodipine besylate to treat hypertension. Azilva, a once-daily angiotensin II type 1 (AT1) receptor...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Clinical News

Azilsartan medoxomil regulatory update

Takeda said that within the first 8 months of this year, it submitted a regulatory application for azilsartan medoxomil in Hong Kong to treat hypertension. The oral angiotensin II type 1 (AT1) receptor blocker (ARB)...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Clinical News

Edarbyclor azilsartan medoxomil/chlorthalidone regulatory update

Takeda said that within the first 8 months of this year, it submitted regulatory applications for azilsartan medoxomil/chlorthalidone in Taiwan, Thailand and Indonesia to treat hypertension. Takeda markets the fixed-dose combination of azilsartan medoxomil, an...